Artelo Biosciences, Inc.
ARTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001621221
No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Artelo Biosciences, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- −2 vs. Q1 2022
- Shares held
- 1.40M
- −52.8K (−3.6%) vs. Q1 2022
- Total value
- $442.8K
- −$209.2K (−32.1%) vs. Q1 2022
- New holders
- 1
- 6 more added
- Sold out
- 3
- 2 more reduced
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 10 | $132.0K |
| Q1 2026 | 11 | $829.9K |
| Q4 2025 | 10 | $120.6K |
| Q3 2025 | 9 | $151.7K |
| Q2 2025 | 9 | $220.1K |
| Q1 2025 | 8 | $75.8K |
| Q4 2024 | 6 | $36.6K |
| Q3 2024 | 5 | $25.6K |
| Q2 2024 | 6 | $35.7K |
| Q1 2024 | 7 | $37.2K |
| Q4 2023 | 7 | $34.4K |
| Q3 2023 | 8 | $76.4K |
| Q2 2023 | 6 | $78.4K |
| Q1 2023 | 7 | $110.8K |
| Q4 2022 | 8 | $337.9K |
| Q3 2022 | 9 | $464.0K |
| Q2 2022 | 15 | $442.8K |
| Q1 2022 | 18 | $659.0K |
| Q4 2021 | 22 | $992.0K |
| Q3 2021 | 17 | $1.57M |
| Q2 2021 | 20 | $3.29M |
| Q1 2021 | 15 | $2.17M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Artelo Biosciences, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 683,896 | $217.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 187,066 | $59.0K | 0.00% | +19,240+11.5% | Added |
| Snowden Capital Advisors LLC | 110,000 | $34.0K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 86,016 | $27.0K | 0.00% | −587−0.7% | Reduced |
| Susquehanna International Group, LLP | 80,080 | $25.0K | 0.00% | +69,148+632.5% | Added |
| Northern Trust Corp | 62,521 | $20.0K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 63,193 | $20.0K | 0.00% | +39,392+165.5% | Added |
| UBS Group AG | 48,961 | $16.0K | 0.00% | +30,678+167.8% | Added |
| HighTower Advisors, LLC | 44,000 | $14.0K | 0.00% | +18,000+69.2% | Added |
| StoneX Group Inc. | 15,000 | $4.75K | 0.00% | +15,000 | New |
| State Street Corp | 13,039 | $4.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 4,856 | $2.00K | 0.00% | −14,867−75.4% | Reduced |
| Wells Fargo & Company | 283 | $0 | 0.00% | +23+8.8% | Added |
| Creative Financial Designs Inc | 1,075 | $0 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 300 | $0 | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −182,619−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −27,952−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −18,227−100.0% | Sold out |
| Keystone Wealth Partners | – | – | – | – | Not filed |